Overview

Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine

Status:
Completed

Trial end date:
2011-03-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Monoclonal antibodies, such as cetuximab and trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving cetuximab together with trastuzumab may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of trastuzumab when given together with cetuximab and to see how well it works in treating patients with metastatic pancreatic cancer that progressed after previous treatment with gemcitabine.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Institut du Cancer de Montpellier - Val d'Aurelle

Treatments:

Cetuximab
Gemcitabine
Trastuzumab